Emicizumab was approved as a first-line therapy for severe bleeding disorders in 2017. According to a study, infants with hemophilia A who received monoclonal antibody emicizumab experienced few bleeding events and no serious complications.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.